Medication info
Hygliamex XR Tablets 100/1000 mg (Sitagliptin, Metformin)

Hygliamex XR Tablets 100/1000 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Light blue, biconvex, oval prolonged-release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300604 · Approved 2023.02.17 · Insurance code 670609070

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The 100/1000 mg extended-release tablets should be taken as 1 tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate glycemic control with concomitant therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by utilizing both sitagliptin and metformin. Patients implementing dietary and exercise therapies can expect additional blood sugar improvement effects. Accordingly, this medication is used in the treatment of type 2 diabetes by effectively helping manage blood sugar levels.

How to take

Adult dose

In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The 100/1000 mg extended-release tablets should be taken as 1 tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate glycemic control with concomitant therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication consists of two active ingredients, both of which are used for the treatment of diabetes. The first component helps regulate blood sugar, but caution is needed as some patients may experience severe allergic reactions. If symptoms like skin rash or difficulty breathing occur, discontinue taking this medication immediately and consult a doctor. Additionally, this medication can cause a serious side effect known as pancreatitis, which is inflammation of the pancreas, so if abdominal pain or vomiting occurs during use, notify a healthcare professional immediately. The second component may be risky for patients with poor renal function, particularly in cases of moderate or severe renal impairment, this medication should not be taken. This medication should not be administered to patients with acute heart disease, heart failure, severe infections, or dehydration; and it must be discontinued prior to radiological examinations. Pregnant or breastfeeding women should not use this medication for safety reasons. While taking this medication, regular kidney function tests are necessary, and those with liver function abnormalities or excessive alcohol consumption should take special care. Additionally, hypoglycemic symptoms may occur if blood sugar becomes too low, so it is advisable to eat regularly and avoid excessive exercise. Patients scheduled for surgery should stop taking this medication 48 hours before the procedure and resume only after confirming that kidney function has returned to normal post-surgery. This medication has been reported to cause side effects such as joint pain, skin rash, muscle pain in some patients, so consult healthcare professionals if any unusual symptoms occur. Lastly, the risk of hypoglycemia may increase when this medication is taken with other antihyperglycemic agents or certain medications, so if you are taking other medications, be sure to inform your healthcare provider. This medication's safety has not been established in children, and dosage adjustments should be considered in elderly patients with regard to kidney function.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • severe hypoglycemia
  • increased serum creatinine
  • elevated liver enzymes
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute renal failure
  • constipation
  • severe and disabling arthralgia
  • blistering dermatosis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also advisable to store it at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness for a longer time.

Appearance and packaging

Appearance

Light blue, biconvex, oval prolonged-release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.